At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 32 enrolled
Drug / intervention
Carfilzomib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase 1b/2, Multicenter, Open-label Study of Carfilzomib, Carboplatin, and Etoposide in Subjects With Previously Untreated Extensive-stage Small-cell Lung Cancer
In Brief
A Phase 2 clinical trial evaluating Carfilzomib, Carboplatin, and 1 other intervention for Extensive-Stage Small-Cell Lung Cancer. Completed, enrolled 32 participants across 17 sites in 3 countries.
Detailed Summary
The purpose of this study is to determine the maximum tolerated dose and assess the safety, tolerability and activity of carfilzomib given in combination with carboplatin and etoposide as initial therapy for patients with extensive-stage small-cell lung cancer (ES SCLC).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsExtensive-Stage Small-Cell Lung Cancer
CountriesCanada, Russia, United States
Collaborators--
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
Enrollment StartNov 2013
First PostedNov 2013
Primary CompletionAug 2016
Study CompletionMay 2017
TodayJul 2026
First PostedNov 19, 2013
Enrollment StartNov 5, 2013
Primary CompletionAug 1, 2016
Study CompletionMay 4, 2017
TodayJul 2, 2026
Enrollment to primary: 2.7 yearsPosted 12.6 years ago
Interventions
Carfilzomibdrug
Administered by intravenous infusion.
Carboplatindrug
Administered by intravenous infusion.
Etoposidedrug
Administered by intravenous infusion.